Articles
Annual Cardiovascular-related Hospitalization Days Avoided With Tafamidis Treatment in Patients With Transthyretin Amyloid Cardiomyopathy
- Journal/Conference:
- Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021 (Sept 10 - 13, 2021; Denver, CO)
- Author(s):
- Rozenbaum, M.: Tran, D.: Bhambri, R.: Nativi-Nicolau, J.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Cardiac
- Condition:
- ATTR cardiomyopathy
Modelling Lifetime Survival Gain in Patients With Transthyretin Amyloid Cardiomyopathy and Baseline NYHA Class III: An Analysis of ATTR-ACT and Long-Term Extension Study
- Journal/Conference:
- Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021 (Sept 10 - 13, 2021; Denver, CO)
- Author(s):
- Rozenbaum, M.: Tran, D.: Li, B.: Bhambri, R.: Postma, M.: Masri, A.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Cardiac
- Condition:
- ATTR cardiomyopathy
Efficacy classification of modern therapies in multiple sclerosis
- Journal/Conference:
- Journal of Comparative Effectiveness Research
- Author(s):
- Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Häring DA, Stoneman D, Klotz L, Adlard N.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Nervous System
- Condition:
- Multiple Sclerosis
Network Meta-analysis of Disease-modifying Therapies for Relapsing Multiple Sclerosis Based on Confirmed Disability Progression: Investigating the Influence of Cross-trial Differences in Endpoint Definition
- Journal/Conference:
- 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 13-15 October 2021 [online]
- Author(s):
- Stoneman D, Drudge C, Zhao M, Worthington E, Cameron C, Haring DA, Samjoo I, Adlard N
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Nervous System
- Condition:
- Multiple Sclerosis
Relapse Reduction by Disease-modifying Therapies for Relapsing Multiple Sclerosis: A Network Meta-analysis
- Journal/Conference:
- 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 13-15 October 2021 [online]
- Author(s):
- Stoneman D, Drudge C, Zhao M, Worthington E, Cameron C, Haring D, Samjoo I, Adlard N
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Nervous System
- Condition:
- Multiple Sclerosis
Cost effectiveness of Ofatumumab in Comparison With Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
- Journal/Conference:
- ISPOR EU 2021
- Author(s):
- Thomas, K.; Adlard, N.; Cooney, P.; Blanchette, F.; Patel, BP.; Baharnoori, M.; Bhan, V.; Clift, F.; Grima, D.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Immune
- Condition:
- Relapsing-Remitting Multiple Sclerosis
Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
- Journal/Conference:
- PharmacoEconomics - Open
- Author(s):
- Bonifacio, M,: Maheshwari, V.: Tran, D.: Agostoni, G.: Filioussi, K.: Viana, R.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Blood, Oncology
- Condition:
- chronic myeloid leukemia
Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review
- Journal/Conference:
- BMC Neurology
- Author(s):
- Ramirez, A.O.; Keenan, A.; Kalau, O.; Worthington, E.; Cohen, L.; Singh, S.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Immune
- Condition:
- Multiple Sclerosis
Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis
- Journal/Conference:
- Rheumatology
- Author(s):
- Philip J. Mease, Iain B. McInnes, Lai-Shan Tam, Kiefer Eaton, Steve Peterson, Agata Schubert, Soumya D. Chakravarty, Anna Parackal, Chetan S. Karyekar, Sandhya Nair, Wolf-Henning Boehncke, Christopher Ritchlin
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Immune
- Condition:
- Psoriatic Arthritis
Matching-Adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline PASI from week 4-40
- Journal/Conference:
- ISPOR EU 2021
- Author(s):
- Sanyal, C.; Situ, A.; Alulis, S.; Hassan, F.; Peterson, S.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Immune
- Condition:
- Psoriasis